Literature DB >> 26971243

Hepatitis C virus quasispecies and pseudotype analysis from acute infection to chronicity in HIV-1 co-infected individuals.

R Bridget Ferns1, Alexander W Tarr2, Stephane Hue3, Richard A Urbanowicz2, C Patrick McClure2, Richard Gilson4, Jonathan K Ball2, Eleni Nastouli5, Jeremy A Garson3, Deenan Pillay6.   

Abstract

HIV-1 infected patients who acquire HCV infection have higher rates of chronicity and liver disease progression than patients with HCV mono-infection. Understanding early events in this pathogenic process is important. We applied single genome sequencing of the E1 to NS3 regions and viral pseudotype neutralization assays to explore the consequences of viral quasispecies evolution from pre-seroconversion to chronicity in four co-infected individuals (mean follow up 566 days). We observed that one to three founder viruses were transmitted. Relatively low viral sequence diversity, possibly related to an impaired immune response, due to HIV infection was observed in three patients. However, the fourth patient, after an early purifying selection displayed increasing E2 sequence evolution, possibly related to being on suppressive antiretroviral therapy. Viral pseudotypes generated from HCV variants showed relative resistance to neutralization by autologous plasma but not to plasma collected from later time points, confirming ongoing virus escape from antibody neutralization.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiretroviral therapy; Founder virus; HCV pseudotype neutralization; HCV quasispecies; HIV-1 co-infection; Single genome sequencing

Mesh:

Substances:

Year:  2016        PMID: 26971243     DOI: 10.1016/j.virol.2016.02.003

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  1 in total

1.  Deep sequencing is an appropriate tool for the selection of unique Hepatitis C virus (HCV) variants after single genomic amplification.

Authors:  Thibault Guinoiseau; Alain Moreau; Guillaume Hohnadel; Nicole Ngo-Giang-Huong; Celine Brulard; Patrick Vourc'h; Alain Goudeau; Catherine Gaudy-Graffin
Journal:  PLoS One       Date:  2017-03-31       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.